Mirae Asset Global Investments Co. Ltd. Has $110,000 Stake in Tenet Healthcare Co. (NYSE:THC)

Mirae Asset Global Investments Co. Ltd. trimmed its stake in shares of Tenet Healthcare Co. (NYSE:THC) by 37.6% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 858 shares of the company’s stock after selling 517 shares during the period. Mirae Asset Global Investments Co. Ltd.’s holdings in Tenet Healthcare were worth $110,000 as of its most recent SEC filing.

A number of other large investors have also recently added to or reduced their stakes in the company. Plato Investment Management Ltd acquired a new position in shares of Tenet Healthcare during the third quarter worth about $28,000. Financial Management Professionals Inc. boosted its position in Tenet Healthcare by 2,222.2% during the 3rd quarter. Financial Management Professionals Inc. now owns 209 shares of the company’s stock worth $35,000 after acquiring an additional 200 shares during the last quarter. True Wealth Design LLC acquired a new stake in shares of Tenet Healthcare in the third quarter valued at approximately $38,000. Spire Wealth Management grew its position in Tenet Healthcare by 19.5% in the fourth quarter. Spire Wealth Management now owns 558 shares of the company’s stock valued at $70,000 after purchasing an additional 91 shares in the last quarter. Finally, Hantz Financial Services Inc. bought a new stake in Tenet Healthcare during the third quarter worth about $83,000. Institutional investors own 95.44% of the company’s stock.

Analyst Upgrades and Downgrades

THC has been the topic of several recent analyst reports. KeyCorp lowered their price target on Tenet Healthcare from $200.00 to $185.00 and set an “overweight” rating on the stock in a research report on Tuesday, January 7th. Truist Financial reduced their target price on Tenet Healthcare from $190.00 to $175.00 and set a “buy” rating for the company in a research note on Monday, January 6th. StockNews.com cut Tenet Healthcare from a “buy” rating to a “hold” rating in a research note on Thursday. Barclays decreased their price objective on shares of Tenet Healthcare from $190.00 to $161.00 and set an “overweight” rating on the stock in a report on Thursday. Finally, JPMorgan Chase & Co. reaffirmed an “overweight” rating and set a $175.00 target price on shares of Tenet Healthcare in a report on Tuesday, December 17th. Four equities research analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $163.19.

Tenet Healthcare Price Performance

THC stock opened at $133.40 on Friday. Tenet Healthcare Co. has a 1 year low of $88.57 and a 1 year high of $171.20. The company has a debt-to-equity ratio of 2.35, a current ratio of 1.58 and a quick ratio of 1.52. The stock has a market cap of $12.69 billion, a price-to-earnings ratio of 4.27, a P/E/G ratio of 0.63 and a beta of 2.05. The company has a 50 day simple moving average of $133.32 and a 200 day simple moving average of $148.13.

Tenet Healthcare (NYSE:THC) last announced its quarterly earnings results on Wednesday, February 12th. The company reported $3.44 EPS for the quarter, beating analysts’ consensus estimates of $2.95 by $0.49. Tenet Healthcare had a return on equity of 24.05% and a net margin of 14.91%. Research analysts anticipate that Tenet Healthcare Co. will post 11.37 EPS for the current fiscal year.

Tenet Healthcare Profile

Tenet Healthcare Corporation operates as a diversified healthcare services company in the United States. The company operates through two segments: Hospital Operations and Services, and Ambulatory Care. Its general hospitals offer acute care services, operating and recovery rooms, radiology and respiratory therapy services, clinical laboratories, and pharmacies.